U.S. Federal Trade Commission : Combatting the Issue of Junk Patents / Saurabh Bhattacharya.

Format:

Book

Author/Creator:

Bhattacharya, Saurabh, author.

Agnihotri, Arpita, author.

Series:

SAGE business cases.

SAGE business cases

Language:

English

Subjects (All):

Strategic planning--Case studies.

Strategic planning.

Physical Description:

1 online resource

Other Title:

United States Federal Trade Commission

Place of Publication:

London : SAGE Publications: SAGE Business Cases Originals, 2025.

Summary:

In April 2024, the U.S. Federal Trade Commission (FTC) combatted the challenge of junk patents filed by pharma companies by disputing more than 300 pharmaceutical patent listings across 20 different brand-name drugs. Junk patents are patents filed with the intent of delaying competitors' entry into the product market rather than claiming a genuine innovation. The FTC asserted that these patents were invalid and that pharma companies filed them to inhibit competition. The FTC intended to promote competition and lower drug prices for consumer welfare. The U.S. Patent and Trademark Office (USPTO), which grants patents and registered trademarks, sometimes approved junk patents as it faced a severe talent crunch with agents not having ample time to evaluate each application appropriately. Increasing the life of patents was important for pharma companies. Otherwise, with the introduction of generic drugs, the prices of many medicines could drop by as much as 20%, and as the market becomes crowded with more generic versions, prices may drop by 20% to 85%. Students will be asked to evaluate several issues. Why did pharma companies file for junk patents? How can the FTC resolve the issue of excessive drug pricing? How can USPTO functioning be improved for effective patent evaluation? What is the optimal strategy for pharma companies to maximize profits from innovation?.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

9781071981597

1071981595

OCLC:

1483993393